Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma
2011

SOX2 Expression in Early-Stage Breast Cancer

Sample size: 95 publication Evidence: moderate

Author Information

Author(s): Claudia Lengerke, Tanja Fehm, Ralf Kurth, Hans Neubauer, Veit Scheble, Friederike Müller, Friederike Schneider, Karen Petersen, Diethelm Wallwiener, Lothar Kanz, Falko Fend, Sven Perner, Petra M. Bareiss, Annette Staebler

Primary Institution: University of Tuebingen

Hypothesis

Does SOX2 expression play a role in breast carcinogenesis and metastatic potential?

Conclusion

SOX2 is expressed in various early-stage postmenopausal breast carcinomas and may promote metastatic potential.

Supporting Evidence

  • SOX2 expression was detected in 28% of invasive breast carcinoma samples.
  • High SOX2 expression was associated with larger tumor size and positive lymph node status.
  • Metastatic lymph nodes showed higher SOX2 expression compared to primary tumors.

Takeaway

This study found that a protein called SOX2 is present in many early breast cancers, and it might help the cancer spread.

Methodology

Immunohistochemistry and FISH were used to analyze SOX2 expression in tumor samples from postmenopausal breast cancer patients.

Potential Biases

Potential selection bias due to the retrospective nature of the study.

Limitations

The study's findings may not be generalizable beyond postmenopausal patients and require further validation in larger cohorts.

Participant Demographics

Patients were postmenopausal women aged 50 to 69 years.

Statistical Information

P-Value

0.018

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-42

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication